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Abstract
The essential G1-cyclin, CCND1, is a collaborative nuclear oncogene that is frequently overexpressed in cancer. D-type
cyclins bind and activate CDK4 and CDK6 thereby contributing to G1–S cell-cycle progression. In addition to the
nucleus, herein cyclin D1 was also located in the cytoplasmic membrane. In contrast with the nuclear-localized form of
cyclin D1 (cyclin D1NL), the cytoplasmic membrane-localized form of cyclin D1 (cyclin D1MEM) induced transwell
migration and the velocity of cellular migration. The cyclin D1MEM was sufﬁcient to induce G1–S cell-cycle progression,
cellular proliferation, and colony formation. The cyclin D1MEM was sufﬁcient to induce phosphorylation of the serine
threonine kinase Akt (Ser473) and augmented extranuclear localized 17β-estradiol dendrimer conjugate (EDC)mediated phosphorylation of Akt (Ser473). These studies suggest distinct subcellular compartments of cell cycle
proteins may convey distinct functions.

Introduction
The cyclin D1 (CCND1) gene, encodes the regulatory
subunit of a holoenzyme that phosphorylates and inactivates the retinoblastoma protein (pRB), in order to promote cell cycle progression1–3. Newly synthesized cyclin
D1 associates with CDK4/6 to form the holoenzyme that
phosphorylates pRB, releasing E2F family transcription
factors and inducing a gene expression network contributing to G1/S entry. Early studies demonstrated that
cyclin D1 functions as a nuclear collaborative oncogene4.
In this regard a cyclin D1 cDNA clone contributed to
cellular transformation by complementing a transformation defective adenovirus E1A oncogene4. The requirement for cyclin D1 in oncogenic transformation has been
established through cyclin D1 anti-sense5,6 and genetic
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deletion studies in the mouse7–9. Furthermore, cyclin D1
targeted to the mammary gland was sufﬁcient for the
induction of mammary tumorigenesis10,11. Clinical studies
have shown a correlation between cyclin D1 expression
and tumorigenesis and increased cyclin D1 expression is
associated with tumor invasion and metastasis12–15.
A growing body of evidence provides support for an
extranuclear function of cyclin D1. Cyclin D1 is actively
synthesized and located exclusively in an extranuclear
location in hibernating hematopoietic stem cells (HSC)16,
in postmitotic neurons17, cardiomyocytes18, and hepatocytes19. The cytoplasmic sequestration of cyclin D1 is
important to maintain the non-proliferative state as
nuclear enforced expression using a nuclear-localized
form of cyclin D1 forces the cell into a proliferative
state18. Cyclin D1 has been identiﬁed in the cytoplasmic
membrane20–22 and shown to bind and regulate the
function of several cytoplasmic membrane-associated
proteins including PACSIN II (Protein kinase C and
Casein kinase Substrate In Neurons protein 2)23 also
known as syndapin), Filamin A24 and paxillin21.
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Fig. 1 Cyclin D1 is located in the cytoplasmic membrane. a The human diploid ﬁbroblast cell line (MRC-5) was stained for cyclin D1, PACSIN II,
and F-actin. Merged images demonstrate the presence of cyclin D1 at the membrane (arrow), shown at high magniﬁcation in the right-side panel.
Size bar is 20 μm. b Cyclin D1 co-staining with tyrosine phosphorylated Paxillin (Y118) and F-actin. Focal contacts are identiﬁed by the tyrosine
phosphorylated Paxillin. c Co-staining of PACSIN II with tyrosine phosphorylated Paxillin (Y118) with merged staining shown by yellow arrows.

The association of cyclin D1 with cytoplasmic membrane proteins21,23,24 is consistent with prior studies
demonstrating other components of the cell-cycle control
apparatus are located in the cytoplasmic membrane
including p27Kip1 and p16INK4a 20,25. Although the physiological function of cytoplasmic membrane-associated
cell-cycle components was previously not well understood, p16INK4a and CDK6 colocalize in membrane rufﬂes
of spreading cells and functioned upstream of αvβ3dependent activation of PKC to regulate matrixdependent cell migration25. Cyclin D1-deﬁcient mouse
embryo ﬁbroblasts (MEFs) and mammary epithelial cells
exhibit increased adhesion and decreased motility compared with wild-type MEFs26–28. Transduction of cyclin
D1−/− cells with a human or murine cyclin D1 cDNA,
reversed this adhesive phenotype, promoting cell migration26. The induction of cell migration by cyclin D1 correlated with the reduction of Rho GTPase activity26.
Mutational analysis demonstrated that cyclin D1 reduction of cellular adhesion and induction of cellular
migration were independent of the pRB- and p160
coactivator-binding domains26. Cyclin E knockin of cyclin
D1−/− MEFs rescued the DNA synthetic defect of cyclin
D1−/− MEFs but did not rescue the migration defect26
suggesting the pRB binding of cyclins and the promigratory function may be dissociable.
Although cyclin D1 binds cytoplasmic membraneassociated proteins and correlative studies have
Oncogenesis

suggested that cyclin D1 may promote cellular migration,
no studies have selectively uncoupled the functional
activity of the nuclear vs. cytoplasmic cyclin D1 pools. The
current studies were conducted in order to determine the
function of cyclin D1 when localized to either the cellular
membrane or the nucleus.

Results
Cyclin D1 is located at the cytoplasmic membrane

The endogenous cytoplasmic membrane-associated
protein PACSIN II was shown to bind cyclin D1 in liver
tissue23 and cyclin D1 bound to PACSIN II and paxillin
(Pxn) in 3T3 cells21,23. In order to characterize the function of membrane-associated cyclin D1, studies were
conducted in the human diploid ﬁbroblast cell line (MRC5) and human breast cancer samples. Using immunohistochemistry, endogenous cyclin D1 was identiﬁed at the
MRC-5 cellular leading edge, in proximity with PACSIN
II (Fig. 1a, Fig. S1). Paxillin (Pxn) is a structural and
regulatory component of FAs and is also found along the
cell membrane. Cyclin D1 was identiﬁed co-staining with
tyrosine phosphorylated paxillin (Paxillin-PTyr118 Fig. 1b,
Fig. S2A). PACSIN II and tyrosine phosphorylated paxillin
colocated at the leading edge Fig. 1c, Fig. S2B), consistent
with prior studies conducted of the individual proteins in
other cell types21,23,24.
Inﬂammatory breast cancer (IBC) is very aggressive
breast cancer linked to poor prognosis. In order to assess
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Fig. 2 Cytoplasmic membrane-associated cyclin D1 promotes transwell migration. a Western blot analysis of 3T3 cells in which cellular
subfractionation has been conducted. The subcellular fractions are characterized for enrichment of the nucleus (Histone H2A), cytoplasm (α-tubulin),
or the cell membrane (Na+/K+ ATPase). b Schematic representation of the expression plasmids used for targeting cyclin D1 to the cytoplasmic
membrane (pECFP-D1 (pECFP-D1MEM)) or nuclear targeted cyclin D1 (Cherry-D1, (Cherry-D1NUC)). c Transwell migration assays of cyclin D1−/− 3T3
cells rescued with expression vectors encoding either cyclin D1WT or d nuclear localized cyclin D1NUC (cherry-D1NUC) or e membrane-associated
cyclin D1MEM (pECFP-D1MEM). f Data are shown as mean ± SEM for N = 5.

the location of cyclin D1 in human breast cancer we
compared membrane-associated cyclin D1 in patients
with IBC and other breast cancers. Samples from 6 IBC
patients and 17 non-IBC patients were stained for cyclin
D1 and analyzed by a clinical pathologist (Fig. S3A, B).
The subcellular distribution was assigned using the
standard Aperio digital analysis algorithm for cellmembrane staining. The entire slide was scanned
enabling analysis of >1000 cells per sample. Five of six
IBCs stained for membrane associated cyclin D1, whereas
only 2/17 non IBCs stained for membrane-associated
cyclin D1. Cytoplasmic-membrane associated cyclin D1
was observed in 5 of 6 IBC patient samples and 2 of 17
non-IBC patient samples had membrane-associated cyclin
D1 (Fig. S3). All 6 IBC and 16 of 17 non-IBC patients had
nuclear localized cyclin D1. We next conducted immunoﬂuorescent studies for cyclin D1 in non-IBC patients in
order to provide more sensitive detection of membraneassociated cyclin D1. Costaining of cancer cells with a
Oncogenesis

pan-cytokeratin antibody and underexposing the immunoﬂuorescence (IF) signal provides an effective way of
delineating the cellular boundaries, revealing tumor cores
with clusters of cells displaying membrane-associated
cyclin D1. In a tissue microarray of 50 ERα-positive breast
cancers examined, membrane-associated cyclin D1 was
detected in four cases (Fig. S3C–F).
Cytoplasmic membrane-targeted cyclin D1 promotes
transwell cellular migration and increases cellular
migratory velocity

Cyclin D1 is known to promote cellular migration of
ﬁbroblasts and mammary epithelial cells26,28. In order to
further characterize the molecular mechanisms by which
cyclin D1 governs the induction of cellular migration we
conducted subfractionation of nuclear and cytoplasmic
cellular fractions from cyclin D1WT vs cyclin D1−/− 3T3
cells (Fig. 2a). Western blot analysis demonstrated
enrichment of histone H2A in the nuclear fraction,
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Fig. 3 Membrane-associated cyclin D1 promotes cellular migratory velocity. a Time lapse videomicroscopy analysis was used to determine
migration velocity of cyclin D1−/− 3T3 cells rescued with expression encoding either cyclin D1WT or b nuclear localized cyclin D1NUC (cherry-D1NUC) or
c membrane-associated cyclin D1MEM (pECFP- D1MEM). d Data are shown as mean ± SEM for N = 20.

α-tubulin in the cytoplasmic fraction and Na+/
K+-ATPase in the membrane-associated fraction as previously described29. Cyclin D1 was identiﬁed in each of
the subcellular fractions, consistent with prior studies
conducted by confocal microscopy21,23. In order to
determine the function of the cytoplasmic membranelocalized fraction of cyclin D1, cyclin D1−/− 3T3 were
transduced with a cyclin D1 expression vector encoding
either cyclin D1WT, cyclin D1NUC, or cyclin D1MEM (Fig.
2b) and functional analysis were conducted. Cherry-lacRNLS-CD1NUC which encodes a nuclear localized form of
cyclin D1, was previously well characterized30,31. Cyclin
D1 was cloned at the C-terminus of the Cherry-lacR-NLS
vector32,33. For cyclin D1MEM the cyclin D1 cDNA was
cloned in frame to pECFP-Mem (Clonetech), which
encodes a fusion protein consisting of the N-terminal 20
amino acids of neuromodulin, also called GAP-43, and a
cyan ﬂuorescent variant of the enhanced green ﬂuorescent
protein. The neuromodulin fragment contains a signal for
posttranslational palmitoylation of cysteines 3 and 4 that
targets ECFP to cellular membranes. Expression of ECFPMem in mammalian cells results in strong labeling of the
plasma membrane and had been used to target proteins
including ERα to the plasma membrane34. Using electroporation the transfection efﬁciency was >90%. Cyclin
D1WT enhanced transwell migration twofold (Fig. 2c, f),
cyclin D1NUC did not enhance transwell migration (Fig.
2d, f) and cyclin D1MEM enhanced transwell migration
threefold (Fig. 2e, f).
Transwell migration assays were next conducted in
MCF-7 cells that were serum starved to reduce
Oncogenesis

endogenous cyclin D1. Compared with the respective
vector control transwell migration was enhanced 6.6-fold
by cyclin D1WT, 2.2-fold by cyclin D1NUC and 12.6-fold by
cyclin D1MEM (Fig. S4).
Cyclin D1-deﬁcient ﬁbroblasts show the same diameter
size as wild-type cells, but attach and spread more rapidly
after seeding on ﬁbronectin-coated plates26,28. Herein,
time lapse video microscopy demonstrated the induction
of cellular velocity by cyclin D1WT (Fig. 3a, d). Expression
of Cyclin D1MEM, but not cyclin D1NUC, promoted cellular migratory velocity (Fig. 3b–d).
The subcellular distribution of cyclin D1MEM and
cyclin D1NUC, was further characterized using confocal
microscopy (Fig. S5). Transfected cells were examined
by confocal microscopy and by Z series reconstruction
with the nucleus stained with Hoechst 33342. The cells
expressing membrane-associated cyclin D1 showed
green ﬂuorescence predominantly at the cellular
membrane (Fig. S5A, B), whereas the cyclin D1NUC
showed red ﬂuorescence predominantly in the nucleus
(Fig. S5C, D).
Cytoplasmic membrane-targeted cyclin D1 augments DNA
synthesis and contact independent growth

Reintroduction of cyclin D1 into cyclin D1−/− ﬁbroblasts may enhance DNA synthesis associated with a
reduction in the proportion of cells in the G0/G1 phase of
the cell cycle. In order to determine the capacity of
membrane-targeted cyclin D1 to regular the cell-cycle
distribution, ﬂuorescence activated cell sorting (FACS)
analysis was conducted. Comparison was made to the
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Fig. 4 Membrane-associated cyclin D1 promotes S-phase entry. a Fluorescence activated cell sorting of cyclin D1−/− 3T3 cells rescued with
expression encoding either cyclin D1WT or c, d nuclear localized cyclin D1 (cherry-CD1NUC) or e, f membrane localized cyclin D1 (pECFP-D1 MEM). b, d,
f Data for cell-cycle distribution are shown as mean ± SEM.

empty control vector because of the potential impact of
ﬂuorescent proteins on apoptotic and cell-cycle control
proteins35. The distribution of cells in each phase of the
cell cycle assessed by FACS demonstrated cyclin D1WT,
cyclin D1NUC, and cyclin D1MEM enhanced the proportion
of cells in the DNA synthetic (S) phase with a doubling of
the proportion of cells in S phase by cyclin D1WT (7.2 vs.
18.2%) (Fig. 4a, b), an 80% increase in S phase by cyclin
D1NUC (10.7 vs. 18.7%) (Fig. 4c, d) and a doubling of the
proportion of cells in S phase by cyclin D1MEM (5.35 vs.
12.2%) (Fig. 4e, f).
Cellular proliferation was assessed by MTT activity with
comparison made to the control vector. Cellular proliferation was increased by cyclin D1WT (2.4 vs. 3.5-fold),
cyclin D1NUC (2.4 vs. 3.1-fold) and cyclin D1MEM (1.6 vs.
2.7-fold) (Fig. 5a). Colony formation as an assay of
contact-independent growth, showed an increase in both
Oncogenesis

colony number and colony size with either cyclin D1WT,
cyclin D1NUC or cyclin D1MEM (Fig. 5d–l) with a twofold
increase in colony number and size with cyclin D1MEM
(Fig. 5j–l). In order to determine potential mechanisms by
which cyclin D1NUC and cyclin D1MEM may induce proliferative signaling, we assessed the impact of signaling
induced using downstream reporter target genes (Fig. S6).
Consistent with prior studies, that cyclin D1 repressed the
(AOX)3-LUC reporter gene36, herein both cyclin D1NUC
and cyclin D1MEM repressed the (AOX)3-LUC reporter
gene (Fig. S6). The immediate early gene c-Fos-LUC and
cyclin D1-LUC were induced approximately twofold more
by cyclin D1MEM than by cyclin D1NUC (Fig. S6). These
studies show that cyclin D1MEM activates immediate early
gene c-Fos and cyclin D1 transcription and suggest that
cyclin D1MEM may promote distinct signaling pathways to
augment cellular growth.
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Fig. 5 Membrane-associated cyclin D1 is sufﬁcient for the induction of both the size and number of new colonies formed. a Cyclin D1−/−
3T3 cells rescued with expression encoding either cyclin D1WT or (nuclear localized cyclin D1 (cherry-D1NUC) or membrane associated cyclin D1
(pECFP-D1 MEM) were analyzed for (a–c), cellular proliferation determined by the MTT assay or (d–l), colony formation assays. The data are shown for
either the colony number or colony size as mean ± SEM for N = 5 separate experiments. Statistical analysis was conducted using the student t test,
and the P value is shown in the ﬁgure.

Cytoplasmic membrane-targeted cyclin D1 augments
estrogen-dependent Akt kinase activation via K112

The estrogen receptor α (ERα) is known to convey both
genomic and extra genomic activities37. The extranuclear
estrogen signaling pathway is thought to involve a
membrane-associated ERα, which activates PI3-kinase
Oncogenesis

and thereby Akt signaling38. Maximal activation of Akt
requires phosphorylation on the carboxy-terminal site,
S473, by mTORC239,40. In recent studies, membraneassociated estrogen signaling was shown to occur via
cyclin D132. We investigated the impact of expressing
cyclin D1 as either total, nuclear, or membrane-tethered
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Fig. 6 Membrane-associated cyclin D1 augments Akt signaling
induced by estrogen. a Western blot analysis of MCF-7 cells
transduced with expression vectors encoding cyclin D1 located to the
nucleus (cherry-D1NUC), the cytoplasmic membrane (pECFP-D1MEM) or
cyclin D1 expressed in both compartments (Total-MSCV-D1TOT). Cells
were treated with E2 (10 nM) for 10 min. Vinculin is a protein loading
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cytoplasmic membrane targeted cyclin D1MEM-WT or cyclin D1MEM-KE
were treated with 17β estradiol dendrimer conjugate (EDC, 10 nM) for
the time points indicated and Western blot conducted for Akt or a
phosphorylated substrate (pAkt Ser 473). S.E. short exposure, L.E. long
exposure.

forms of cyclin D1 (Fig. 6). The human breast cancer cell
line (MCF-7) was transduced with expression vectors
encoding cyclin D1 targeted to the nucleus (CherryCD1NUC), to the cytoplasmic membrane (PECFPCD1MEM) or expressed in both cytoplasmic and nuclear
compartments (MSCV-CD1TOT). Increased expression of
cyclin D1 via an MSCV expression vector (cyclin D1WT),
resulted in increased cyclin D1 abundance and increased
phosphorylation of Akt1 at Ser473 compared with vector
control (Fig. 6a, lanes 1 vs. 2). The ectopic expression of
cyclin D1MEM enhanced phosphorylation of Akt1 at
Ser473 compared with vector control (Fig. 6a, lanes 3 vs.
4). Estradiol (E2) increased phosphorylation of Akt1 at
Ser473 compared with vehicle control (Fig. 6a, lanes 7 vs.
1). The ectopic expression of cyclin D1MEM increased E2induced phosphorylation of Akt1 at Ser473 compared
with vehicle control (Fig. 6a, lanes 10 vs. 4).
The extranuclear vs. nuclear E2-induced signaling
pathways can be distinguished using 17β-estradiol linked
Oncogenesis

Cytoplasmic membrane-targeted cyclin D1 augments EDCdependent Akt kinase activation at the cell membrane

We conducted IF to assess the relative abundance and
subcellular distribution of Akt1 Serine 473 phosphorylation upon EDC treatment in cells transduced with the
distinct located forms of cyclin D1. MCF-7 cells
expressing the membrane-associated cyclin D1 (PECFPCD1MEM) showed the characteristic enrichment of
membranous GFP staining (Fig. 7a). Akt1 phosphorylated at Serine473 may be either nuclear or cytoplasmic,
related to additional signaling partners45. In the vehicle
treated cells, cyclin D1MEM expression was associated
with the induction of nuclear p-Ser473-Akt1. EDC
treatment of vector control cells increased nuclear pSer473-Akt1. EDC treatment of cyclin D1MEM transduced MCF-7 cells correlated with the induction of pSer473-Akt1, which was found to be in a cytoplasmic
membranous distribution (Fig. 7a). In MCF-7 cells
transduced with cyclin D1NUC, cyclin D1-RFP was
located primarily in the nucleus. Nuclear localized
cyclin D1 (cherry-CD1NUC) did not induce p-Ser473Akt1 signiﬁcantly (Fig. 7b). EDC treatment of MCF-7
cells augmented phosphorylation p-Ser473-Akt1, which
was primarily nuclear in distribution (Fig. 7b). Careful
quantitation evidenced that cyclin D1NUC did not augment EDC-induced nuclear Akt1 Serine473 phosphorylation (Fig. 7b, d). MCF-7 cells transduced with cyclin
D1TOT showed nuclear, cytoplasmic, and membraneassociated cyclin D1, and an enhancement of EDC
induced Akt1 Serine473 phosphorylation. p-Ser473Akt1 was located in both the nucleus and membrane
(Fig. 7c, d). Thus, the cytoplasmic membrane localized
cyclin D1 (PECFP-CD1MEM), but not the nuclear localized form (cherry-CD1NUC), augmented Akt1 phosphorylation at Serine473.
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Fig. 7 Membrane-associated cyclin D1 augments Akt1 Ser473 phosphorylation induced by extranuclear localized estradiol dendrimer
(EDC). a Immunohistochemical staining for MCF-7 cells expressing either an expression vector for cyclin D1 tethered to the cytoplasmic membrane
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The immediate activation of Akt1 by insulin requires cyclin
D1

Recent studies identiﬁed a dichromic ﬂuorescent (DCF)
dye substrate for cellular Akt1 activity46. The diserine
DCF substrate was shown to serve as a speciﬁc substrate
for Akt1, which can be used to quantitatively assess the
enzyme’s activity in real time46. Insulin activation of cellular Akt phosphorylates a single serine residue of the
diserine DCF substrate in a time dependent manner,
resulting in a spectral shift that can be used to assess
longitudinally the stimulation and reversibility of Akt1
activity. The dichromic dye LS456 is phosphorylated by
Akt1, but not a variety of other kinases (including PKA,
PKC, RSK1, P70S6K, and PI3K)46. The binding of insulin
to its cell surface receptor stimulates phosphoinositide-3
kinase (PI3K), which then induces the second messenger,
phosphotidylinositol-3, 4, 5-triphosphate (PIP3). PIP3
activates Akt and additional downstream effectors. As
LS456 was shown to serve as a speciﬁc substrate for Akt1
in response to 150 nM insulin, we examined the kinetics
of insulin-mediated activation of LS456 in cyclin D1−/−
MEF compared with wild-type MEFs. Insulin stimulation
of Akt1 activity assessed by LS456 was delayed with
Oncogenesis

reduced induction in cyclin D1−/− cells compared with
the cyclin D1WT rescued cells (Fig. S7).
Cyclin D1 restrains RhoA activity via K112

In the current studies, cytoplasmic membrane-tethered
cyclin D1 augmented cellular migratory velocity and
estrogen-dependent induction of Akt1 Ser473 phosphorylation. In prior studies cyclin D1 rescue of cyclin D1−/−
MEFs reduced RhoA activity26. Although these prior
studies suggested that cyclin D1 may augment cellular
migration by restraining RhoA activity, Rac1 and Cdc42
can also participate in cellular migration47. In order to
examine the functional interactions with cyclin D1 and
Rho GTPases we deployed the FRET based ﬂuorescent
probes for RhoA, Rac, and Cdc42 (Fig. 8a). pRaichu-RhoA
consists of a truncated RhoA (aa 1–189), the RhoAbinding domain (RBD) and the FRET pair of CFP and
YFP. When RhoA binds to GTP, and thereby the RBD,
RhoA recruits CFP in close proximity to YFP, thereby
increasing the FRET activity between CFP and YFP. We
examined the functional interaction between cyclin D1
and RhoA using FRET. The image from a typical FRET
experiment was shown in Fig. 8b. Cells were
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Fig. 8 Cyclin D1 restrains RhoA activity assessed by FRET. a Schematic representations of pRaichu-RhoA (RhoA (aa 1–189) bound to GDP or GTP.
YFP and CFP denote a yellow and cyan-emitting mutant of GFP, respectively. RhoA-binding domain (RBD) indicates the RBD of the effector protein. b
Representative image of cellular membrane associated emission at 534 and 481 nm before and after photobleaching. c Emission spectra of pRaichuRhoA expressed in HEK-293T cells at an excitation wavelength of 453 nm (left) with ﬂuorescence intensity mapped before (blue) and after (red)
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co-transfected with pRaichu-RhoA and either cyclin
D1WT, cyclin D1KE, or their corresponding vector control.
Spectral images in 10 channels from 470 to 566 nm with
excitation at 458 nm were simultaneously recorded. YFP
was inactivated by photobleaching with a 514 nm laser at
Oncogenesis

100% power output (Fig. 8b). The emission spectra within
the ROI increased in the CFP signal at 481 nm after
photobleaching with YFP which has an emission peak at
534 nm (Fig. 8c). FRET efﬁciency was used to quantitatively compare the difference in RhoA activity among the
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cells. (FRET efﬁciency was deﬁned as (FB − F0)/FB × 100%,
where FB is the intensity of the donor (CFP) after photobleaching and F0 is the intensity of the donor before
photobleaching, see “Methods”). FRET efﬁciency was
reduced 40% by cyclin D1WT but was not signiﬁcantly
reduced by expression of the cyclin D1KE (Fig. 8d). Similar
analysis of FRET for the related Rho family members,
Rac1 and Cdc42, failed to elicit changes in FRET efﬁciency upon re-expression of cyclin D1 wild type. By using
FRET, we extend prior studies demonstrating cyclin D1
reduces Rho GTPase activity26, to deﬁne the interaction of
cyclin D1 occurs with RhoA, not Rac or Cdc42, and
demonstrate the residue K112 of cyclin D1 is required for
interaction with RhoA.

Discussion
The well characterized nuclear functions of cyclin D1
include ﬁrstly, serving as the regulatory subunit of a
holoenzyme that phosphorylates the pRB protein, and
secondly serving as part of a transcriptional regulatory
complex that drives proliferative gene expression48.
Consistent with previous studies, that either identiﬁed
cyclin D1 associated with the cytoplasmic membrane or
cytoplasmic membrane proteins20–24, the current studies
identiﬁed cyclin D1 colocalized with PACSIN II and
paxillin PTyr118 at the cytoplasmic membrane. The
current studies extend our understanding of cyclin D1
through characterizing the function and signaling pathways regulated by cyclin D1 at the cytoplasmic membrane
vs. the nucleus. Firstly, herein membrane-associated
cyclin D1 augmented transwell migration and enhanced
the velocity of cellular migration. In contrast, the nuclearlocalized form of cyclin D1 neither enhanced cellular
migratory velocity nor induced transwell migration in 3T3
cells. These studies are consistent with previous ﬁndings
that cyclin D1 promotes migration21,26,28,43,44, but extend
these ﬁndings by demonstrating that it is the membraneassociated form of cyclin D1 that mediates this function.
Secondly, these studies show both nuclear and
membrane-associated cyclin D1 augment cellular DNA
synthesis, cellular proliferation, and contact-independent
growth. Thirdly, these studies demonstrate that cyclin D1
tethered to the cytoplasmic membrane induces Akt signaling, characterized by the induction of Akt1 Ser473
phosphorylation. Furthermore, membrane-associated
cyclin D1 augmented a physiological function of estrogen, to induce Akt1 Ser473 phosphorylation. Fourthly, as
activity of Rho GTPase at the cellular membrane may
inhibit cellular adhesion and migration and restrain Akt
activity49, we examined and deﬁned a role for cyclin D1 to
inhibit Rho activity. Collectively these studies deﬁne a
novel function for cytoplasmic membrane associated
cyclin D1 that may augment aberrant growth control and
cellular invasion.
Oncogenesis
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Prior studies had shown the induction of cellular
migration by cyclin D121,26,28,43,44. Cyclin D1−/− cells
show a more spread morphology than the corresponding
wild type and display an increased number of focal
adhesions (FAs) with higher levels of tyrosinephosphorylated paxillin21,26,28,43,44. Herein, using cyclin
D1−/− cells, we demonstrated the membrane-associated
pool of cyclin D1 is sufﬁcient to augment transwell
migration. We identiﬁed cyclin D1 at the plasma membrane in inﬂammatory breast cancer, and cyclin D1
colocalized to the cytoplasmic membrane with PACSIN II
and Paxillin (Y118) in MRC-5 cells. Cyclin D1 was previously shown by mass spectrometry to bind the
membrane-associated proteins PACSIN II23, Filamin A24,
Paxillin21, and several additional proteins50. PACSIN II is
involved in cell spreading51, as well as endocytosis of
cell–surface receptors like the EGF receptor52 and in
caveolae-mediated endocytosis53,54. In view of clinical
analyses showing a correlation between total cyclin D1
expression and tumor invasiveness and metastasis12–15,
our studies suggest further studies assessing membraneassociated cyclin D1 may be warranted.
Herein, cytoplasmic membrane-associated cyclin D1
augmented phosphorylation of Akt1 at Ser473. Akt, also
known as Protein Kinase B, promotes cellular survival,
proliferation, growth, and migration55. Akt hyperactivation contributes to human cancer correlating with poor
prognosis and therapy resistance and genetic deletion
demonstrated Akt1 is required for ErbB2-induced breast
cancer progression and tumor metastases in vivo56.
Herein the acute nongenomic E2 activation of Akt1, was
augmented by the membrane-associated cyclin D1 pool.
Estradiol acutely activates Akt57,58 in part through the
association of ERα at the plasma membrane associated
with the p85 regulatory subunit of PI3-kinase and other
proteins including the scaffold protein caveolin-1, G
proteins, Src kinase, Ras, and Shc57,59–61. ERα regulates
nuclear gene expression via genomic and extranuclear
non-genomic signals37,59. Extranuclear pools of ERα
reside in the plasma membranes62 and the ability to distinguish nuclear from extranuclear ERα signaling has
been enabled through the generation of a 17β-estradiol
dendrimer conjugate (EDC) which is localized to the
extranuclear compartment41,42. Herein, using nuclear
excluded E2 dendrimers, cyclin D1 was shown to participate in the acute non-genomic E2 response. Genetic
deletion studies in the mouse demonstrated E2-dependent
induction of genes governing growth factors, growth
factor receptor and promigratory processes in the mammary gland requires cyclin D163. The biological effects of
estrogen, are critically dependent upon cyclin D1
in vivo63,64, with the current studies suggesting an
important component is mediated via membraneassociated cyclin D1.
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RhoA, Rac1, and Cdc42 are the best characterized
members of the Rho GTPase branch of the Ras superfamily and are known to regulate cellular morphology and
migration47. In the current studies, cyclin D1 restrained
RhoA activity, requiring K112. Cyclin D1−/− cells have
increased RhoA activity, increased ROCK II kinase and
increased LIM kinase activation (threonine 505/508). LIM
kinase phosphorylation at threonine 505/508 in turn
phosphorylates the actin-depolymerizing protein coﬁlin at
serine 3 and MLC2 at Thr18/Ser1926. Herein, FRET
analysis evidenced cyclin D1 restrained Rho GTPase
activity. In contrast, neither Rac-GTPase nor Cdc42
activity was inﬂuenced by cyclin D1. The reduction in
RhoA GTPase FRET by cyclin D1 was abolished by
mutation of cyclin D1 residue K112. Cyclin D1 participates in multiple functions via K112 including CDK4/6mediated pRB phosphorylation65 and binding to
p27KIP144. Rho GTPase is an important modulator of ERα
activity66,67, and E2 enhances ERα association with the
p85 subunit of PI3 kinase thereby inducing Akt phosphorylation57. An increase in ERα/PI3K interactions in
patient-derived xenografts (PDXs) correlates with
acquired resistance to tamoxifen68. RhoA represses Akt
Ser473 phosphorylation49 and the repression of RhoA
activity by cyclin D1 may have contributed to the induction of pAkt1–Ser473. The role of cyclin D1 in restraining
RhoA, thereby inducing ERα activity and tamoxifen
resistance, warrants further investigation.
Several lines of evidence support the importance of
cyclin D1 nuclear location in aberrant growth including
elegant studies showing that a mutant of cyclin D1
(D1T286A), that is defective in phosphorylation-mediated
nuclear export, induces cell transformation in cell culture
assays and triggers B-cell lymphoma in a mouse model of
mantle cell lymphoma69,70. Furthermore, transgenic mice
that overexpress the identical mutant cyclin D1 driven by
the MMTV promoter (MMTV-D1T286A) developed
mammary adenocarcinoma with a shorter latency relative
to mice over-expressing the wild-type cyclin D1 (MMTVD1)71. That said, the current studies suggest that in
addition to the nuclear function of cyclin D1, a
membrane-associated pool of cyclin D1 contributes to
cellular migration, induction of Akt1 activity and the
induction of a signaling pathway, deﬁned through transcriptional reporters, that activates the immediate early
gene c-Fos and cyclin D1. c-Fos is a target of Akt1
induction and Fos family members induce cell-cycle entry
though the induction of cyclin D172, suggesting a
mechanism by which membrane associated cyclin D1 may
augment cellular growth. The major adjuvant therapy for
the ~70% of ERα expressing human breast cancer involves
anti-estrogen therapy. The ERα/PI3K/Akt complex pathway is hyperactivated in aggressive breast tumors73. The
non-genomic actions of E2/ERα, mediated via cytoplasmic
Oncogenesis
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membrane-associated cyclin D1, may provide an important additional target58. As membrane-associated cyclin
D1 augments activity of the ERα/PI3K/Akt complex
pathway, the cytoplasmic membrane pool of cyclin D1
may be a new target for ERα expressing breast cancer
treatments74,75.

Materials and methods
A detailed description is provided in the Supplementary
Materials.
Plasmids and tissue culture

The cyclin D1+/+ and cyclin D1−/− MEFs10 were prepared as described previously76.
Transwell migration

The assessment of transwell migration77, migratory
velocity, and migratory distance26 were conducted as
previously described.
Fluorescence resonance energy transfer (FRET) imaging

HEK293T cells, co-transfected with 3×FLAG vector,
cyclin D1 wild-type or cyclin D1KE mutant and FRET
reporters (pRaichu-RhoA, pRaichu-Cdc42 or pRaichuRac178,79), were cultured in a four-well chamber and
imaged using a Zeiss laser-scanning microscope,
LSM510META, with a 40× oil immersion Doc PlanNeoﬂuar lens objective (numerical aperture of 1.3). To
detect FRET between CFP and YFP, we used time-lapse
and lambda stack acquisition linked with the photobleaching command80.
Immunostaining

IF staining and confocal microscopy of cultured cells
was conducted as described previously77. Chromogen
immunostaining of human breast cancer samples was
conducted on the breast tissue with the Ventana Benchmark autostainer using deintiﬁed archival tissue which are
exempt from review by the Thomas Jefferson University
Institutional Review Board. Fluorescence-based immunohistochemistry for cyclin D1 multiplexed with pancytokeratin and DAPI counterstain was performed as
previously described81–83 on a tissue microarray containing cores of 50 de-identiﬁed ER-positive breast cancer
specimens provided by the Medical College of Wisconsin
Tissue Bank under IRB-approved protocol.
Live cell Akt activity monitoring

Live cell imaging studies were conducted as described46.
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